FindTrial
Sign In

Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review.

Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review. - omalizumab for seasonal allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040561
Enrollment
Unknown
Registered
2020-06-01
Start date
2020-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seasonal allergic rhinitis

Interventions

None listed

Sponsors

Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A randomized controlled trial evaluating the efficacy and safety of omalizumab in patients with controlled seasonal allergic rhinitis.

Exclusion criteria

Exclusion criteria: Case reports, case-control studies, cohort studies, and single-arm studies.

Design outcomes

Primary

MeasureTime frame
daily nasal symptom score any adverse events—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp+81-3-37848532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026